Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy.

Abstract

This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.

• Authors: Maria Ioanna Stefanou, Eleni Karachaliou, Maria Chondrogianni, Christos Moschovos, Eleni Bakola, Aikaterini Foska, Konstantinos Melanis, Elisabeth Andreadou, Konstantinos Voumvourakis, Matilda Papathanasiou, Eleni Boutati, Georgios Tsivgoulis
• Journal: Neurological research and practice (Neurol Res Pract) Vol. 4 Issue 1 Pg. 6 (Feb 08 2022) ISSN: 2524-3489 [Electronic] England
• PMID: 35130960 (Publication Type: Letter)
• Copyright: © 2022. The Author(s).